

CONTENTS

<i>List of contents</i>	<i>Page</i>
Introduction	1
Aim of the work	3
Review of literature:	4
• <i>Pharmacology of anticoagulants</i>	4
• <i>Heparin induced thrombocytopenia</i>	31
• <i>Diagnosis and monitoring of HIT</i>	47
• <i>Treatment of HIT</i>	59
Patients and methods	73
Results	78
Discussion	90
Conclusion	95
Recommendation	96
Summary	97
References	98
Arabic summary	--

LIST OF TABLES

<i>Tables No.</i>	<i>list of tables of review</i>	<i>Page</i>
Table 1:	Heparin dosing monogram	8
Table 2:	Pharmacokinetics of DITs	21
Table 3:	Causes of thrombocytopenia	34
Table 4:	Types of heparin induced thrombocytopenia	36
Table 5:	The "4 T's" Assessment point system for patients with suspected HIT	50
Table 6:	Guidelines for platelet count monitoring for HIT	53
Table 7:	Venous and arterial thrombosis associated with heparin–induced thrombocytopenia and thrombosis syndrome (HITT)	85
Table 8:	Treatment protocol for bivalirudin anticoagulation during cardiopulmonary bypass	64
Table 9:	Dosing adjustment for lepirudin	67
Table 10:	Fondaparinux as a potential treatment for HIT	70
Table 11:	Treatment of HIT according to 4T scores system	71
Table 12:	The 4T score system	74
Table 13:	Demographic and baseline characteristics	79
Table 14:	HIT according to platelet count	80
Table 15:	Platelets count at baseline and follow up	81
Table 16:	HIT according to age	83
Table 17:	HIT according to sex	83

Table 18:	HIT according to type of treatment	83
Table 19:	HIT according to type of heparin	83
Table 20:	HIT according to previous exposure to heparin	84
Table 21:	HIT in pregnant and non pregnant females	84
Table 22:	HIT according to site of thrombosis	84
Table 23:	Clinical probability of HIT	85
Table 24:	Predictors of HIT	85

LIST OF FIGURES AND GRAPHS

<i>Figure No.</i>	<i>List of figures</i>	<i>Page</i>
<i>Fig. (1):</i>	Mechanism of action of heparin	6
<i>Fig. (2):</i>	Mechanism of action of direct thrombin inhibitors as compared with heparin	20
<i>Fig. (3):</i>	Mechanism of thrombosis in HIT	40
<i>Fig. (4)</i>	Model of HIT antibody interactions with endothelial cells	41
<i>Fig. (5):</i>	Model of pathogenesis in HIT and thrombosis	41
<i>Fig. (6):</i>	Assay for testing heparin-dependent antibodies associated with HIT	56
<i>Fig. (7)</i>	Algorithm outlining care of patients with heparin-induced thrombocytopenia	60
<i>Graph. (1)</i>	HIT according to platelet count	86
<i>Graph. (2)</i>	study group according to final results	86
<i>Graph. (3)</i>	clinical probability of HIT	87
<i>Graph. (4)</i>	HIT according to age	87
<i>Graph. (5)</i>	HIT according to sex	87
<i>Graph. (6)</i>	HIT according to type of treatment	88
<i>Graph. (7)</i>	HIT according to type of heparin	88
<i>Graph. (8)</i>	HIT according to previous exposure to heparin	88
<i>Graph. (9)</i>	HIT according to site of thrombosis	89
<i>Graph. (10)</i>	Treatment of HIT	89
<i>Graph. (11)</i>	Outcome of HIT	89

LIST OF ABBREVIATION

ACS	Acute coronary syndrome
ACT	Activating clotting time
ADP	Adenosine diphosphate
AF	Atrial fibrillation
APTT	Activated partial thromboplastin time
AT III	Anti thrombin III
CPB	Cardiopulmonary bypass
DA	Dalton
DIC	Disseminated intravascular coagulopathy
DTI	Direct thrombin inhibitors
DVT	Deep venous thrombosis
ECT	Ecarin clotting time
EDTA	Ethylenediaminetetraacetic
EIA	Enzyme immunoassay
ELISA	Enzyme linked immunosorbent assay
FDA	Food and drug administration
HIPA	Heparin induced platelet activation
HIT	Heparin induced thrombocytopenia
HS	Heparin sulfate
ICU	Intensive care unit

IG..... Immunoglobulin

INR..... International normalized ratio

IV..... Intravenous

LMWH..... Low molecular weight heparin

NSAIDS..... Non steroidal anti-inflammatory drugs

PCI..... Percutaneous coronary intervention

PF4..... Platelet factor 4

PT..... Prothrombin time

SC..... Subcutaneous

TEC..... Thromboembolic complication

TMB..... Tetramethyle buzidine

TT..... Thrombin time

TTP..... Thrombotic thrombocytopenic purpura

TXA2..... Thromboxane A2

UFH..... Unfractionated heparin

U/H..... Unit/hour

US..... United States